PMID- 21261617
OWN - NLM
STAT- MEDLINE
DCOM- 20110909
LR  - 20191210
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 41
IP  - 7
DP  - 2011 Jul
TI  - 8-Hydroxy-2'-deoxyguanosine is a prognostic mediator for cardiac event.
PG  - 759-66
LID - 10.1111/j.1365-2362.2010.02465.x [doi]
AB  - BACKGROUND: DNA in the nucleus is one of the major targets of reactive oxygen 
      species (ROS), and oxidative DNA damage has been implicated in the pathogenesis 
      of chronic heart failure. 8-Hydroxy-2'-deoxyguanosine (8-OHdG) is produced from 
      deoxyguanosine in DNA by ROS. The purpose of this present study was to examine 
      the clinical significance of serum 8-OHdG levels in patients with heart failure. 
      METHODS: We measured serum 8-OHdG levels in 230 patients with chronic heart 
      failure and 42 control subjects without heart failure by sandwich enzyme-linked 
      immunosorbent assay. Patients were prospectively followed during a median 
      follow-up period of 472 days with the end points of cardiac death or progressive 
      heart failure requiring re-hospitalization. RESULTS: Serum 8-OHdG concentrations 
      were higher in patients with heart failure than in control subjects (P < 0.001) 
      and increased with advancing New York Heart Association (NYHA) functional class 
      (P < 0.001). Normal upper limit of 8-OHdG level was determined as mean +/- 2SD 
      value from 42 control subjects (0.40 ng mL(-1)). Abnormally high serum 8-OHdG 
      levels (> 0.40 ng mL(-1)) were observed in 21.2%, 43.1%, 42.6% and 69.4% through 
      NYHA I to IV (P < 0.001). A total of 66 cardiac events occurred during a 
      follow-up period, and Kaplan-Meier survival curves demonstrated that cardiac 
      event rate was markedly higher in patients with high 8-OHdG levels than in those 
      with normal 8-OHdG levels (62.4% vs. 29.6%, P = 0.0007). CONCLUSIONS: Serum 
      8-OHdG levels provide important prognostic information for the risk 
      stratification of patients with heart failure.
CI  - (c) 2011 The Authors. European Journal of Clinical Investigation (c) 2011 Stichting 
      European Society for Clinical Investigation Journal Foundation.
FAU - Suzuki, Satoshi
AU  - Suzuki S
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine, Yamagata, Japan.
FAU - Shishido, Tetsuro
AU  - Shishido T
FAU - Ishino, Mitsunori
AU  - Ishino M
FAU - Katoh, Shigehiko
AU  - Katoh S
FAU - Sasaki, Toshiki
AU  - Sasaki T
FAU - Nishiyama, Satoshi
AU  - Nishiyama S
FAU - Miyashita, Takehiko
AU  - Miyashita T
FAU - Miyamoto, Takuya
AU  - Miyamoto T
FAU - Nitobe, Joji
AU  - Nitobe J
FAU - Watanabe, Tetsu
AU  - Watanabe T
FAU - Takeishi, Yasuchika
AU  - Takeishi Y
FAU - Kubota, Isao
AU  - Kubota I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110125
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Biomarkers)
RN  - 88847-89-6 (8-Hydroxy-2'-Deoxyguanosine)
RN  - G9481N71RO (Deoxyguanosine)
SB  - IM
MH  - 8-Hydroxy-2'-Deoxyguanosine
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Deoxyguanosine/*analogs & derivatives/blood
MH  - Disease Progression
MH  - Epidemiologic Methods
MH  - Female
MH  - Heart Failure/*blood/diagnostic imaging/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Ultrasonography
EDAT- 2011/01/26 06:00
MHDA- 2011/09/10 06:00
CRDT- 2011/01/26 06:00
PHST- 2011/01/26 06:00 [entrez]
PHST- 2011/01/26 06:00 [pubmed]
PHST- 2011/09/10 06:00 [medline]
AID - 10.1111/j.1365-2362.2010.02465.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2011 Jul;41(7):759-66. doi: 10.1111/j.1365-2362.2010.02465.x. 
      Epub 2011 Jan 25.